Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study
Hossein-Ardeschir Ghofrani1,2,3, Gérald Simonneau4,5, Andrea M D'Armini6, Peter Fedullo7, Luke S Howard8,9, Xavier Jaïs4,5, David P Jenkins10, Zhi-Cheng Jing11, Michael M Madani12, Nicolas Martin13, Eckhard Mayer14, Kelly Papadakis13, Dominik Richard13, Nick H Kim7
1German Center for Lung Research (DZL), Giessen, Germany
2University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany
3Department of Medicine, Imperial College London, London, UK
4Assistance Publique—Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France
5INSERM U-999, Le Kremlin-Bicêtre, France
6Department of Cardio-Thoracic and Vascular Surgery, Heart and Lung Transplantation and Pulmonary Hypertension Unit, Foundation IRCCS Policlinico San Matteo, University of Pavia School of Medicine, Pavia, Italy
7Division of Pulmonary and Critical Care Medicine, University of California San Diego, La Jolla, CA, USA
8National Pulmonary Hypertension Service, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK
9National Heart & Lung Institute, Imperial College London, London, UK
10Department of Cardiothoracic Surgery, Papworth Hospital, Cambridge, UK
11State Key Lab of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
12Division of Cardiovascular and Thoracic Surgery, University of California San Diego Medical Center, San Diego, CA, USA
13Actelion Pharmaceuticals, Allschwil, Switzerland
14Department of Thoracic Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
Lancet Respiratory Medicine,The
Tập 5
785-794
Thông tin tác giả